Works matching AU van Erp, N. P.

Results: 8

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Published in:
2016
By:
- Schneider, T C;
- de Wit, D;
- Links, T P;
- van Erp, N P;
- van der Hoeven, J J M;
- Gelderblom, H;
- Roozen, C F M;
- Bos, M;
- Corver, W E;
- van Wezel, T;
- Smit, J W A;
- Morreau, H;
- Guchelaar, H J;
- Kapiteijn, E;
- Schneider, Tatiana C;
- de Wit, Djoeke;
- Links, Thera P;
- van Erp, Nielka P;
- van der Hoeven, Jakobus J M;
- Gelderblom, Hans
Publication type:
journal article
Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Published in:
Diabetes, Obesity & Metabolism, 2016, v. 18, n. 3, p. 258, doi. 10.1111/dom.12605
By:
- Knapen, L. M.;
- van Dalem, J.;
- Keulemans, Y. C.;
- van Erp, N. P.;
- Bazelier, M. T.;
- De Bruin, M. L.;
- Leufkens, H. G. M.;
- Croes, S.;
- Neef, C.;
- de Vries, F.;
- Driessen, J. H. M.
Publication type:
Article
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.
Published in:
Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 353, doi. 10.1007/s00280-023-04615-7
By:
- Westerdijk, K.;
- Krens, S. D.;
- Steeghs, N.;
- van der Graaf, W. T. A.;
- Tjwa, E. T. T. L.;
- Westdorp, H.;
- Desar, I. M. E.;
- van Erp, N. P.
Publication type:
Article
Myelosuppression by sunitinib is flt-3 genotype dependent.
Published in:
2010
By:
- van Erp, N. P.;
- Mathijssen, R. H. J.;
- van der Veldt, A. A.;
- Haanen, J. B.;
- Reyners, A. K. L.;
- Eechoute, K;
- Boven, E;
- Wessels, J. A. M.;
- Guchelaar, H-J;
- Gelderblom, H
Publication type:
Letter
Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer.
Published in:
European Journal of Clinical Pharmacology, 2018, v. 74, n. 4, p. 465, doi. 10.1007/s00228-017-2394-0
By:
- Willemsen, A. E. C. A. B.;
- Knapen, L. M.;
- de Beer, Y. M.;
- Brüggemann, R. J. M.;
- Croes, S.;
- van Herpen, C. M. L.;
- van Erp, N. P.
Publication type:
Article
Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report.
Published in:
2022
By:
- Verhulst, S. H.;
- Boerrigter, E.;
- Ras, S.;
- van Erp, N. P.;
- Hamberg, P.
Publication type:
Case Study
Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.
Published in:
2016
By:
- Wit, D.;
- Schneider, T.;
- Moes, D.;
- Roozen, C.;
- Hartigh, J.;
- Gelderblom, H.;
- Guchelaar, H.;
- Hoeven, J.;
- Links, T.;
- Kapiteijn, E.;
- Erp, N.;
- de Wit, D;
- Schneider, T C;
- Moes, D J A R;
- Roozen, C F M;
- den Hartigh, J;
- Guchelaar, H J;
- van der Hoeven, J J;
- Links, T P;
- van Erp, N P
Publication type:
journal article
A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.
Published in:
British Journal of Clinical Pharmacology, 2018, v. 84, n. 7, p. 1575, doi. 10.1111/bcp.13591
By:
- ter Heine, R.;
- van Erp, N. P.;
- Guchelaar, H. J.;
- de Fijter, J. W.;
- Reinders, M. E. J.;
- van Herpen, C. M.;
- Burger, D. M.;
- Moes, D. J. A. R.
Publication type:
Article